A Feasibility Study of Octreotide Infusion During Liver Transplant.

Liver Transplantation Clinical Trial

— Octreotide  

Official title:

A Double-blind Randomised Placebo-controlled Feasibility Study to Assess the Impact of Octreotide Infusion During Liver Transplantation on Post-operative Renal Failure.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04941911
• Other study ID #: 17/0508
• Secondary ID: PB-PG-0817-20023
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 27, 2022
• Est. completion date: January 31, 2024

Study information

• Verified date: May 2023
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine whether an octreotide infusion during liver transplantation improves renal outcomes, intraoperative blood pressure and reduces haemorrhage and transfusion requirement.

Description:

Common and serious complications of liver transplantation surgery include renal failure, haemorrhage and blood transfusion. These complications prolong post-operative recovery, increase the risk of liver graft failure, mortality and the need for long-term renal dialysis.

The drug octreotide is a synthetic analogue of somatostatin with comparable physiological effects and a good side-effect profile. Existing evidence in liver transplantation supports octreotide efficacy in improving renal function, reducing bleeding and enhancing blood pressure. However, there is no robust randomised controlled trial evidence for octreotide in liver transplantation and limited safety data regarding its use in this setting.

This is a multi centre, prospective double-blind, randomised, placebo-controlled trial of octreotide infusion during liver transplantation. The patients will be randomised in a 2:1 ratio to either octreotide or placebo groups. Stratified randomisation of patients is by donation type (DCD vs. DBD).

Patients will be randomised in the anaesthetic room and study medication given as an initial bolus of 5ml (100mcg octreotide or saline) prior to surgical incision and then continued throughout surgery at 5ml/hr (100mcg/hour octreotide or saline).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: January 31, 2024
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults aged 18 years and over undergoing primary liver transplantation of a whole or partial liver graft from a cardiac or brain dead donor.

• Provision of written informed consent.

Exclusion Criteria:

• Previous solid organ transplant.

• Acute liver failure.

• Fulminant hepatic failure.

• Patients receiving a living donor liver graft.

• Patients currently admitted to ICU prior to transplantation.

• Requirement of haemodialysis or CVVHF pre-operatively.

• Known allergy or adverse reaction to octreotide.

• Pre-operative decision to use intra-operative CVVHF.

• A positive pregnancy test.

Related Conditions & MeSH terms

• Liver Transplantation
• Renal Failure
• Renal Insufficiency

Intervention

Drug:
• Octreotide Acetate
Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.

Other:
• Placebo
Sodium chloride 0.9% w/v

Locations

Country	Name	City	State
United Kingdom	University Hospital Birmingham	Birmingham
United Kingdom	Royal Free Hospital	London

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Fabes J, Ambler G, Shah B, Williams NR, Martin D, Davidson BR, Spiro M. Protocol for a prospective double-blind, randomised, placebo-controlled feasibility trial of octreotide infusion during liver transplantation. BMJ Open. 2021 Dec 2;11(12):e055864. doi: 10.1136/bmjopen-2021-055864. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability to recruit patients.	This will be assessed by: • Ability to recruit patients (target: = 30% consent rate of eligible patients admitted for transplant)	Approximately 180 days.
Primary	Completion of the study intervention.	This will be assessed by: • The percentage of patients successfully completing the study intervention. Defined as eligible patients who receive the entire study drug infusion in a blinded manner.	Approximately 9.5 hours.
Secondary	The incidence of acute kidney injury.	This will be defined by Acute Kidney Injury Network stage 1 criteria (a 50% increase in serum creatinine from baseline or less than 0.5 ml/kg/hr urine output for 6-12 hours post-transplant).	Within 24, 72 and 168 hours post-operatively.
Secondary	Post-operative incidence of a new requirement for renal replacement therapy.	Administration of haemofiltration or haemodiafiltration.	Within 24 hours, 72 hours, one and two weeks post-operatively.
Secondary	Incidence of new chronic kidney disease or deterioration of chronic kidney disease.	This is defined as a new persistent estimated glomerular filtration rate below 60 ml/min/1.73m2 or a decline in pre-existing glomular function to a more severe KDIGO chronic kidney disease. status.	At thirty and ninety days post operative.
Secondary	Incidence of early allograft dysfunction.	Early allograft dysfunction defined by the presence of one or more of the following: total bilirubin = 10 mg/dL (171 µmol/L) or, INR = 1.6 on day 7, and ALT/AST > 2,000 IU/L within the first 7 days post-operatively.	At day seven post-operatively
Secondary	Patient mortality.	Patient mortality at thirty and ninety days post-operatively.	At thirty and ninety days post-operatively.
Secondary	Intra-operative red blood cell salvage.	Total volume of intra-operative red blood cell salvage available for reinfusion following washing and centrifugation.	Within 24, 72 and 168 hours post-operatively.
Secondary	Volume of packed red blood cell transfusion.	Volume of packed red blood cell transfusion administered intra-operatively and at 24, 72 and 168 hours post-operatively.	Intra-operatively and at 24, 72 and 168 hours post-operatively.
Secondary	Incidence of adverse events secondary to study drug infusion.	Recorded adverse events are: abnormal QTc interval (460ms in men, 470ms in women) or associated ventricular arrhythmia or Torsades de Pointes, unexpected or resistant hypoglycaemia (blood sugar < 4mM) and clinical suspicion of allergic or anaphylactic reaction.	Intra-operatively and up to 24 hours post-operatively.
Secondary	PROMs_ data collection_1	PROMs (Patient Recorded Outcome Measures) of quality of life . The questionnaires to be used to quantify quality of life is EuroQoL-5D-5L.	For EuroQoL-5D-5, At Day 1 and at thirty and ninety days post-operatively. Then at 3, 6 & 9 months.
Secondary	PROMs_ data collection_2	PROMs (Patient Recorded Outcome Measures) of quality of life . The questionnaires to be used to quantify quality of life is LDQOL.	For LDQOL, At Day 1 and at thirty and ninety days post-operatively. Then at 3, 6 & 9 months.